Thirty-two subjects completed the study, with no serious adverse events, dose-limiting safety findings or tolerability issues leading to withdrawal

No drug-related serious adverse events or dose-limiting toxicities were observed in either of the first two cohorts

No unexpected or serious adverse events were observed

Medgenics Inc., of San Francisco, said there have not been any procedure- or drug-related serious adverse events in the first four patients treated in the Phase IIa trial in Israel of Epodure biopumps for anemia in those on dialysis with end-stage renal disease

One patient suffered serious adverse events that led to discontinuation, but all other side effects were mild and transient

Through 74 weeks, eteplirsen was well tolerated and there were no clinically significant treatment-related adverse events, serious adverse events, hospitalizations or discontinuations

No serious adverse events were reported, and the reported adverse events were mild to moderate and transient in nature

Data showed the drug was well tolerated throughout the study enrolling healthy volunteers, with no dose-limiting toxicities or serious adverse events observed

No serious adverse events were reported

The drug was also well tolerated, with similar rates of occurrence of serious adverse events among drug and placebo groups...There were no product-related serious adverse events in either arm

In addition, statistically significant increases in non-fatal serious adverse events (SAE) were observed in patients on Tredaptive plus statin therapy compared to placebo plus statin therapy

The rate of serious adverse events and the rate of discontinuations due to adverse events were similar between the two groups

After all patients had received three injections, no serious adverse effects or viral rebounds were observed

The committee reviewed the treatment effect at one year on the primary outcome measure of efficacy, change in motor function using the MFM scale, together with the latest safety report, including electrocardiogram traces, periodic laboratory findings, hemostatic parameters and serious adverse events listings for all participants

However, preliminary safety data analyses suggested the benefit/risk ratio might not favor the trabedersen treatment arm due to serious adverse events associated with the local mode of administration, so the company will focus on systemic intravenous administration of trabedersen in glioma...The trial reported no imbalance in serious adverse events, and there were a low number of major adverse cardiovascular events

No serious adverse events or safety concerns were identified

TapImmune Inc., of Seattle, said an interim safety analysis of the first five breast cancer patients treated with HER2/neu Class II antigens did not show any serious adverse events, so treatment of the remaining 17 patients in the Phase I study at the Mayo Clinic will progress

To date, five patients have completed four weeks of treatment, and ACH-3102 has been well tolerated, with no serious adverse events...No serious adverse events were reported, and the drug demonstrated a dose-dependent lowering effect on growth hormone (hGH), as shown by an analysis of the pharmacodynamics effect on hGH, when stimulated by growth hormone-releasing hormone

iCo Therapeutics Inc., of Vancouver, British Columbia, said there have been no drug-related serious adverse events among patients receiving repeat doses of iCo-007 at the midpoint of its Phase II iDEAL study in diabetic macular edema